Amneal Pharmaceuticals, Inc.

DB:2DT Stock Report

Market Cap: €2.6b

Amneal Pharmaceuticals Valuation

Is 2DT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2DT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2DT (€8.05) is trading below our estimate of fair value (€44.14)

Significantly Below Fair Value: 2DT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2DT?

Key metric: As 2DT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 2DT. This is calculated by dividing 2DT's market cap by their current revenue.
What is 2DT's PS Ratio?
PS Ratio1x
SalesUS$2.68b
Market CapUS$2.79b

Price to Sales Ratio vs Peers

How does 2DT's PS Ratio compare to its peers?

The above table shows the PS ratio for 2DT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
DMP Dermapharm Holding
1.6x4.4%€1.9b
BAYN Bayer
0.4x1.1%€19.9b
PSG PharmaSGP Holding
2.7x7.0%€297.4m
2FJ0 Pierrel
3.4xn/a€92.8m
2DT Amneal Pharmaceuticals
1x5.6%€2.8b

Price-To-Sales vs Peers: 2DT is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 2DT's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.2x3.4%
2DT Amneal Pharmaceuticals
 1x5.6%US$2.79b
2DT 1.0xIndustry Avg. 3.2xNo. of Companies33PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.2x20.4%
2DT Amneal Pharmaceuticals
 1x156.0%US$2.79b
No more companies

Price-To-Sales vs Industry: 2DT is good value based on its Price-To-Sales Ratio (1x) compared to the European Pharmaceuticals industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is 2DT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2DT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio2.3x

Price-To-Sales vs Fair Ratio: 2DT is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (2.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2DT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.05
€9.97
+23.9%
10.6%€11.40€8.55n/a4
Nov ’25€7.70
€9.25
+20.1%
12.2%€11.10€8.32n/a4
Oct ’25€7.45
€8.57
+15.0%
5.3%€9.02€8.12n/a4
Sep ’25€7.45
€8.84
+18.7%
4.9%€9.15€8.23n/a3
Aug ’25€6.75
€7.68
+13.8%
5.7%€8.30€7.38n/a3
Jul ’25€5.90
€7.66
+29.9%
5.2%€8.36€7.43n/a4
Jun ’25€6.20
€7.66
+23.6%
5.2%€8.36€7.43n/a4
May ’25€5.45
€6.70
+22.8%
10.1%€7.32€5.72n/a4
Apr ’25€5.55
€6.70
+20.6%
10.1%€7.32€5.72n/a4
Mar ’25€5.50
€6.29
+14.3%
11.4%€7.38€5.54n/a4
Feb ’25€5.05
€6.12
+21.1%
14.5%€7.39€5.08n/a4
Jan ’25€5.45
€5.72
+5.0%
8.9%€6.54€5.14n/a4
Dec ’24€3.90
€5.72
+46.7%
8.9%€6.54€5.14n/a4
Nov ’24€3.58
€4.96
+38.5%
8.2%€5.66€4.72€7.704
Oct ’24€4.02
€4.77
+18.7%
8.2%€5.45€4.54€7.454
Sep ’24€3.72
€4.77
+28.2%
8.2%€5.45€4.54€7.454
Aug ’24€2.88
€3.22
+12.0%
14.3%€3.68€2.76€6.754
Jul ’24€2.60
€3.18
+22.4%
14.3%€3.64€2.73€5.904
Jun ’24€2.32
€3.18
+37.1%
14.3%€3.64€2.73€6.204
May ’24€1.62
€3.63
+124.1%
17.7%€4.54€2.72€5.454
Apr ’24€1.24
€3.69
+197.4%
20.4%€4.61€2.77€5.553
Mar ’24€1.91
€4.64
+143.1%
21.8%€6.37€3.19€5.505
Feb ’24€1.99
€4.64
+133.3%
21.8%€6.37€3.19€5.055
Jan ’24€1.83
€4.93
+169.6%
21.8%€6.77€3.39€5.455
Dec ’23€2.42
€4.93
+103.9%
21.8%€6.77€3.39€3.905
Nov ’23€2.20
€5.87
+167.0%
20.1%€7.09€4.05€3.585

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R76.0b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.90

7D

-6.8%

1Y

6.0%

Pharming Group

€485.0m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-3.4%

1Y

-31.8%

Collegium Pharmaceutical

US$976.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$27.60

7D

-14.3%

1Y

20.0%